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Liver transplantation has become the standard of care for the treatment of a variety of liver 
diseases that in the past would have resulted in an early death.  According to the United Network 
for Organ Sharing (UNOS) there are currently 14,433 candidates waiting for a liver transplant in 
the United States.  A total of 7,841 liver transplants were performed in the United States in 
2016[1].  Despite increased education regarding organ donation and advances in patient 
management, there continues to be a gap in the supply and demand of organs for transplant. Due 
to this scarce resource, pre and post- transplant patient management remains a key focus in 
achieving optimal outcomes.   Transplant medicine is a highly complex, specialized field, 
requiring specialized knowledge and management of the patient in the pre-transplant phase and 
the early post -transplant period.  Patients requiring a liver transplant often are managed in the 
outpatient setting but can require intensive care placement for acute  liver failure or 
decompensated end stage liver disease (ESLD). Critical care nurses play a role in the care of 
these patients.  The best patient outcomes occur when expertise and experience coincide[2]. The 
purpose of this article is to provide critical care nurses with  an overview of liver disease and 




(S)Overview of Liver Function 
The liver is the largest internal organ in the human body. Weighing an average of 3 pounds in the 
average adult, it performs more than 500 critical functions (REF). At any time, it holds one 
quarter of the body’s blood supply, and filters 1.4 liters of blood per minute and is responsible 
for 25% of the cardiac output.  The portal vein supplies 75% of the liver’s blood flow, and the 
remaining 25% of blood supply to the liver comes from the hepatic artery.  Substances 
transported tothe liver may be metabolized, stored, modified, or detoxified and  then released 
into the circulation or intestine to be excreted. The liver plays a vital role in fat metabolism, 
gluconeogenesis, and the metabolism of carbohydrates. It is an important metabolizer of 
proteins, converting amino acids from foods to produce energy, fats, or carbohydrates. The by-
product of this energy conversion is ammonia, which the liver converts to urea which is released 
into the blood, transported to the kidneys, and finally removed from the body in urine.  The liver 
synthesizes several clotting factors, II, VII, IX, X, as well as factor V and factor XI  (Northrup, 
Caldwell).  It plays a primary role in gluconeogenesis and regulates blood glucose levels and 
produces approximately one liter of bile per day. Bile is vital for the absorption of fat-soluble 
vitamins and elimination of toxic substances.  
The liver is the primary site for metabolism of medications through enzymes within the 
Cytochrome P450 (CYP 450) pathways. Drugs that affect these pathways are referred to as either 
inhibitors or inducers; those that cause increased concentrations of other drugs that utilize this 
pathway are inhibitors and can lead to subtherapeutic drug levels. Conversely, drugs that cause 
decreased concentrations are inducers and can cause toxic drug levels to occur.  J Adv Pract 
Oncol. 2013 Jul-Aug; 4(4): 263–268. 
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(S)Causes of Liver Failure 
Liver failure is often categorized as acute or chronic end stage liver disease, resulting in the need 
for a liver transplant to prolong the patient’s life. Inflammation: early stage of liver disease, shows 
it is fighting off infections or heal injury. 
Fibrosis: inflammation untreated liver scars. Scar tissue is unable to do the work that healthy tissue 
can do. At this stage, the scar tissue can be repaired and liver can heal and have improved to normal 
function. 
Cirrhosis: left untreated, significant fibrosis leads to scarring that cannot be reversed. Cirrhosis can 
lead to a variety of chronic liver complications, such as liver cancer. 




(S)Indications for Liver Transplant 
The need for liver transplant is considered when a patient with cirrhosis has signs and symptoms 
of hepatic decompensation in spite of the use of maximized medical therapies (Martin et al 2014 
AASLD Eval for Liver tran in adults 2013). The most common indicators for transplant are 
variceal bleeding from the esophagus and/or stomach, bleeding due to portal hypertension, 
significant coagulopathy, hepatic encephalopathy, spontaneous bacterial peritonitis, and severe 
and persistent ascites. SEE TABLE 1 below from Martin, et al, AASLD Guidelines 2013. Once 
hepatic decompensation develops, the patient with cirrhosis can quickly decompensate since 
additional complications such as sepsis, hepotorenal syndrome, and hepatic carcinoma are likely 
to hasten mortality. 
 
Acute Hepatic Failure 
In the Intensive Care Unit (ICU) patients awaiting liver transplant typically have been 
admitted in acute or “fulminant” hepatic failure (AHF). This is defined as “hepatic 
encephalopathy within 8 weeks from the appearance of clinical evidence of hepatic failure 
without a history of previous liver disease”. (AASLD/UNOS). The clinical presentation typically 
includes hepatic dysfunction, significant coagulopathy, and may include hepatic encephalopathy 
(HE). If left untreated HE may progress to cerebral edema, ultimately leading to multi-organ 
system failure and death occurring in up to half the cases (Acute Liver Failure William Bernal, 
M.D., and Julia Wendon, M.B., Ch.B. N Engl J Med 2013; 369:2525-2534December 26, 
2013DOI: 10.1056/NEJMra1208937).  Although the etiology of acute hepatic failure can be 
due to a variety of factors in the United States the most common cause is due to drug-induced 
injury. Acetaminophen and certain anticonvulsants are well-known for causing AHF, as well as 
undiagnosed autoimmune disease and viruses.  
Signs and symptoms of acute hepatic failure 
• Encephalopathy 
• Cerebral edema and/or associated signs of ICP 
• Jaundice 
• Ascites 
• Right upper quadrant tenderness 
• Change in liver span 
• Hematemesis or melena 
• Hypotension and tachycardia 
 
The development of cerebral edema is a major cause of morbidity and mortality in 
patients with acute liver failure. Studies have demonstrated that an ammonia level  
f >100 lM on admission represent an independent risk factor for the development 
of high-grade hepatic encephalopathy, and a level of >200 lM predicts ICH (AASLD 
Lee,Stravitz, Larson March 2012 Hepatology) 
 
 
TABLE 1 ACUTE LIVER FAILURE COMPLICATIONS OF CIRRHOSIS: 
• Ascites 
• Chronic gastrointestinal blood loss due to portal hypertensive gastropathy 
• Encephalopathy 
• Liver cancer 
• Refractory variceal hemorrhage 
• Synthetic dysfunction 
 
Liver Transplant Evaluation 
Patients with acute fulminant liver failure (AFLF) or end stage liver disease (ESLD) experience 
the sequelae of liver disease, often requiring admission to the intensive care unit ( ICU ) for 
medical management.  Chronic and acute liver failure patients are considered candidates for liver 
transplantation, now a treatment modality to decrease patient death.  Intensive, supportive critical 
care patient management and liver transplantation provides an opportunity for patient survival 
for the majority of patients with acute fulminant liver failure[3]. The one year survival rate for 
patients with a primary (first) liver transplant is 91.8%.[1]. Currently there are approximately 
170 transplant centers in the United States[1].  Patients referred for transplantation will be seen 
and evaluated at a transplant center by the transplant team.  The ICU nurse can work with the 
transplant team to provide psychological support and education to the patient and family during 
the evaluation process.   
 
Transplant centers provide the expertise of a multidisciplinary transplant team approach to the 
evaluation process.  The patient undergoes both physical and psychological testing to determine 
readiness for transplantation and the required long term care post- transplant care. The transplant 
evaluation is described as a 3-fold process with goals of establishing a diagnosis of ESLD; 
excluding any absolute or relative contraindications to transplant; and determining the suitability 
and degree of patient illness to better allocate resources and optimize survival[4].  The transplant 
evaluation process may vary from center to center with patient specific diagnostic testing being 
required.  Common components of the transplant work-up include blood tests, diagnostic 
imaging and testing, psychological evaluation and consultation with other specialist depending 
on the patient’s condition.  Blood testing includes:  liver function tests, PT/INR, a 
comprehensive metabolic panel, CBC with differential,  blood type and screen, hepatitis 
screening (A, B, C), virology screening for cytomegalovirus (CMV), herpes simplex virus(HSV), 
Epstein-Barr virus(EBV) and HIV, tumor markers, including Alpha-fetoprotein(AFP), atrial 
blood gases(ABGs). Patients may require toxicology testing for alcohol and drugs pending the 
etiology of liver disease.  Imaging studies include:  chest radiography, duplex ultrasonography, 
abdominal CT scanning, CT scanning of the chest and pelvis or magnetic resonance angiography 
(MRI) if indicated. Imaging studies are required to detect malignancies in the pre-transplant 
patient.  Pre transplant cirrhotic patients with hepatocellular carcinoma will requiring serial 
scanning to monitor tumor size and to determine treatment modalities pre transplant and tumor 
listing criteria.  Additional tests to exclude malignancies may include: mammography and PAP 
testing for women and PSA for men.  The patient undergoing transplant evaluation will also 
require testing to evaluate cardiac and pulmonary function.  Testing may include:  stress thallium 
scanning, coronary angiography and echocardiography, electrocardiography and pulmonary 
function tests. Upper and lower GI endoscopies to evaluate for esophageal or gastric varices and 
to exclude malignancies of the GI tract may be required.  Patients may require paracentesis for 
treatment of ascites and to rule out spontaneous bacterial peritonitis (SBP).  Consultations and 
medical clearances are usually obtained from the following specialty services: cardiopulmonary, 
psychiatry and social work.  If indicated, nephrology, infectious disease and dental work-ups 
may be needed before the patient can be listed.  Financial clearance is always obtained prior to 
listing a patient for transplant.   
 
Contraindications for liver transplant have become fewer over recent years. Transplant centers 
may vary in defining the relative contraindications specific to certain diseases or psychosocial 
conditions.  Many centers mandate abstinence from alcohol, drug and nicotine use for 6 months 
prior to transplantation with center specific protocols for screening.   A positive screen can render 
the patient inactive on the transplant list and even lead to delisting.  Absolute or relative 
contraindications to transplant are listed in table 1. 
TABLE 1 
Absolute and Relative Contraindications for Liver Transplantation 
Absolute Contraindications Relative Contraindications 
Brain Death or acute liver failure with intracranial 
pressure greater than 50 mm Hg or cerebral 
perfusion pressure less than 40 mm Hg 
 
Advanced age(center specific) 
Active alcohol abuse or drug use Severe malnutrition  
Extrahepatic malignancy Morbid obesity 
Uncontrolled sepsis HIV(center specific) 
Certain medical conditions: advanced cardiac or 
pulmonary disease; acquired immune deficiency 
syndrome 
Multi organ failure 
 
Anatomical abnormality or thrombosis of the 
superior mesenteric vein and portal vein which 
would preclude transplantation 
Cholangiocarcinoma(center specific) 
Persistent noncompliance (center specific) Psychosocial conditions:  dx of mental illness, 
non-compliance, lack of psychosocial support 
5, 6 
 
Organ Allocation and Listing for Transplant 
The Organ Procurement and Transplant Network (OPTN) and the United Network for Organ 
Sharing (UNOS) are responsible for managing the United States organ allocation[7]. Medical 
professionals, transplant recipients and donor families provide input in the national policies 
governing transplant, following the goals of the OPTN  to increase numbers of transplants, provide 
equity to transplant access, improve waitlist, living donor and transplant recipient outcomes, 
promote safety for living donors and transplant recipients and promote efficient management of 
the OPTN [1].     
 Patient disease and illness severity plays a key role in organ allocation and patient listing for 
transplant.  Scoring systems are specified according to age with The Model for End-Stage Liver 
Disease (MELD) used for patients 12 years and older.  The MELD calculator provides a scoring 
system to determine how urgently a patient will need a liver transplant within the next three 
months [1].  The MELD calculates a patient’s score based on the following laboratory tests: 
serum creatinine (mg/dl), bilirubin(mg/dl), INR, and serum sodium (mEq/L).  The serum 
sodium, especially a low sodium level, is variable associated with mortality, independent of the 
MELD score and has recently been added to the MELD calculator[8].  Kidney function is also 
assessed through the question: has the patient had dialysis twice within the last week, or 24 hours 
of CVVHD?  If yes, the creatinine value is automatically registered at 4 mg/dl.  Often patients in 
the ICU setting are requiring dialysis or CVVHD.  The MELD calculation determines organ 
allocation based on the patient’s score and geographic location. Scores range from 6 to 40 with a 
higher score indicating a sicker patient. An exception to this rule are patients that receive  MELD 
exception points based on certain diagnoses such as hepatocellular carcinoma and 
portopulmonary hypertension to account for a higher waitlist mortality not reflected in the 
MELD score [9].  
 In 2013 the Share 35 policy was approved by UNOS mandating regional sharing of livers 
throughout 11 UNOS regions for patients with a MELD of 35 or greater. The Share 15 policy 
provides patients with a MELD of 15 or greater offers from the local organ procurement 
organization (OPO) first and then regionally Critically ill patients in  the ICU setting with a life 
expectancy of seven days or less qualify for a status IA on the UNOS list.  
Status IA organ offers can be from the local, regional or national UNOS list.  If the patient’s 
condition worsens and the patient becomes temporarily too unstable to undergo a liver transplant, 
the patient’s status is changed to a status 7. Status 7 makes the patient inactive on the transplant 
list until stabilization is achieved and the status is updated.  Status The patient’s blood type and 
size are also required for UNOS listing with organ acceptance dependent on donor-patient size 
similarity and blood type compatibility.  
 
Critical care nurses are involved with the ICU team in providing patient stabilization and 
supportive care to prevent further complications until an organ becomes available.  Measures to 
manage the acutely ill pre-transplant patient includes seizure prophylaxis and surveillance; 
treatment of cerebral edema and inter cranial hypertension; management of encephalopathy and 
coagulopathy; mechanical ventilation; treatment of circulatory dysfunction; infection 
surveillance and treatment; nutritional management; and management of fluids, electrolytes and 
glucose [11].  When a suitable organ is found for the patient, the liver transplant is performed 
and the patient returns to the ICU for post- transplant management.  It is important for ICU 
nurses to be familiar with potential complications that can occur, often requiring immediate 
intervention. Early Post-Transplant Complications 
Complications occurring post liver transplant can be categorized into early and late 
complications.  For the purpose of this article, focus will be on the early post- transplant 
complications.  Use of extended criteria donors (ECD) can increase the risk of less than optimal 
patient outcomes, including early complications.  Donor variables known to affect patient 
outcomes include increased age, long hospitalization, extended warm or cold ischemic times and 
donor liver steatosis, leading to reperfusion syndrome, ischemia and graft dysfunction[12, 7]. 
Primary Graft non-function(PGNF) 
Complete graft failure immediately post-transplant without a definitive cause has been defined as 
primary non-function.  This type of liver injury can result in severe liver dysfunction with 
elevation in liver enzymes immediately post-transplant, secondary organ damage due to the liver 
dysfunction, biliary strictures and even re-transplant.  Patients exhibit symptoms of comma, 
coagulopathy, oliguria, hypoglycemia and marked elevation in liver function tests with 
transaminases often greater than 5000 U/L[7]. The critical care nurse must be aware of these signs 
and symptoms of liver dysfunction and alert the transplant team. 
Early Acute Cellular Rejection 
Early acute cellular rejection usually occurs within the first 90 days post liver transplant while 
chronic rejection can occur later post- transplant, and is usually a result of low 
immunosuppression levels.  Acute cellular rejection is usually reversible but chronic rejection 
can affect long term graft and patient survival. Symptoms of acute rejection can include elevated 
LFTs (serum aminotransferases, alkaline phosphatase, gamma-glutamyl transpeptidase (GGT), 
and bilirubin levels), fever, abdominal pain and malaise.   The gold standard to diagnose 
rejection is liver biopsy, percutaneous or transjugular.    Treatment for rejection includes high 
dose corticosteroids, and an increase in immunosuppressant dosing or adding a second agent. 
Patients transplanted for HCV may be treated without the addition of steroids due to the impact 
on HCV progression.  HCV and rejection have similar histological markers, often making 
diagnosis difficult to differentiate.  Patients transplanted with a diagnosis of autoimmune 
hepatitis may require a more aggressive approach to the treatment of rejection, including high 
dose steroids.  It is important to differentiate rejection from infection in the early post liver 
transplant patient to ensure appropriate treatment. 
 
Vascular Complications 
Hepatic Artery Thrombosis 
Hepatic Artery Thrombosis (HAT) has been estimated to occur in 4-12% of adult liver 
transplants with causes including hepatic artery narrowing, kinking or a mismatch with the 
donor- recipient vessels[13].  Hepatic artery thrombosis is diagnosed through Doppler 
ultrasonography.  Re-transplantation is indicated if blood flow cannot be restored to the 
transplanted graft.   
Portal Vein Thrombosis 
Portal Vein Thrombosis(PVT) occurs in approximately 1-13% of liver transplant recipients and 
can be the result of technical problems during the time of surgery, thrombus formation, or a 
hypercoagulable state [13].  A PVT can be diagnoses through ultrasonography showing an 
increase in velocity within the portal vein; CT scanning; an MRI or magnetic resonance 
venography (MRV).  Treatment may include a thrombectomy, transjugular intrahepatic 
portosystemic shunt (TIPS) or re-transplant.  
Biliary Complications 
Liver transplantation requires biliary reconstruction, connecting the common hepatic duct of the  
donor to the native bile duct of the recipient(choledocho-choledochostomy) or connection of the 
donor common bile duct to a portion of the recipient’s jejunum ( Roux-en-Y 
choledochojejunostomy).  The type of biliary reconstruction is determined by surgeon 
preference, underlying liver disease, donor and recipient bile duct size or previous surgeries [14].  
Use of  a temporary biliary stent for an end-to-end biliary connection is also determined by 
transplant surgeon preference.   Depending on stent placement technique, the stent may be 
passed through the GI track or require removal through an endoscopic retrograde 
cholangiopancreatography (ERCP) around three month post- transplant.   The stent is radiopaque 
with  placement or migration can be confirmed on abdominal x-ray.  
Approximately 13-19% of adults receiving a deceased donor liver transplant can have biliary 
complications[13] Biliary complications include biliary strictures and bile leaks. 
Biliary Leaks and Strictures 
 The ICU nurse will be more concerned about biliary leaks in the immediate post operative 
period.  Early biliary leaks are usually a result of technical issues, including lack of perfusion 
from the hepatic artery and occur at the biliary anastomosis.   The patient may present with fever, 
abdominal pain and elevation in liver function tests.  Imaging may include an US, cholangiogram 
or MRCP, showing peritonitis or fluid collections.  An endoscopic retrograde cholangiography 
(ERC) usually is performed for patients with a choledocho-choledochostomy and requiring 
biliary stent placement. Repeat LFTs are usually performed 1-2 weeks post-procedure.  
Depending on the type of stent (plastic or metal), the stent will be removed or exchanged within 
three to six months.  Biliary strictures can be at the site of the anastomosis, usually occurring 
within the first 6- 12 months post- transplant.Bilomas 
 A biloma can occur from biliary necrosis due to hepatic artery thrombosis.  The biloma can be 
perihepatic or within the hepatic parenchyma.  Treatment may include antibiotics, percutaneous 
drainage or surgical repair. 
 
Early Acute Cellular Rejection 
Early acute cellular rejection usually occurs within the first 90 days post liver transplant while 
chronic rejection can occur later post- transplant, and is usually a result of low 
immunosuppression levels.  Acute cellular rejection is usually reversible but chronic rejection 
can affect long term graft and patient survival. Symptoms of acute rejection can include elevated 
LFTs (serum aminotransferases, alkaline phosphatase, gamma-glutamyl transpeptidase (GGT), 
and bilirubin levels), fever, abdominal pain and malaise.   The gold standard to diagnose 
rejection is liver biopsy, percutaneous or transjugular.  The three histological features indicating 
acute cellular rejection are mixed inflammatory infiltrate in the portal triad; destructive or 
nondestructive nonsuppurative cholangitis involving the interlobular bile duct epithelium and 
endotheliitis[16].  Treatment for rejection includes high dose corticosteroids, and an increase in 
immunosuppressant dosing or adding a second agent. Patients transplanted for HCV may be 
treated without the addition of steroids due to the impact on HCV progression.  HCV and 
rejection have similar histological markers, often making diagnosis difficult to differentiate.  
Patients transplanted with a diagnosis of autoimmune hepatitis may require a more aggressive 
approach to the treatment of rejection, including high dose steroids.  It is important to 
differentiate rejection from infection in the early post liver transplant patient to ensure 
appropriate treatment. 
Infection 
 Post- transplant infections can be classified into three periods:  transplant to one month; the 
second through sixth month and greater than six months. In the early post- transplant period, 
patients are at greater risk of infections, especially opportunistic,  due to the high levels of 
immunosuppression.  Bacterial, nosocomial infections are prevalent in the early hospitalized 
period due to central vascular access sites, indwelling catheters and drainage tubes, surgical 
complications, wound infections, and prolonged mechanical ventilation.   C. Difficle infections 
are common during the hospitalization due to immunosuppression and antibiotic treatment. .  
While donors are screened for all types of infections prior to transplant, if unexplained symptoms 
of infection occur, consider the possibility of a donor infection. Infection prophylaxis is started 
during the hospitalization with length of treatment per transplant center protocols. Refer to Table 
2. 
TABLE 2 
Prophylaxis During the Early Post Transplant Period 
Infection      Prophylaxis 
Pneumocystis jirovecii (formerly P. carinii) 
pneumonia (PCP) 
 Trimethoprim-sulfamethoxazole 6-12 
months. 
If allergic use Pentamidine,  Dapsone,  
Atovaquone 
 Cytomegalovirus (CMV)  Ganciclovir IV or Valganciclovir oral 




Hypovolemia during and early post operatively along with high levels of immunosuppressant 
agents with known renal toxicity can cause worsening of kidney function.  It is important for the 
ICU nurse to monitor the patient’s renal function and urine output, observing for worsening 
function, indicating the need for dialysis. Immunosuppression will need to be modified in the 
picture of worsening kidney function due to the nephrotoxic effects of the calcineurin inhibitors ( 
Cyclosporine and Tacrolimus).   
Additional Complications 
Post-operative nursing management includes patient assessment for bleeding, wound infection or 
dehiscence and neurological changes. Coagulopathy and encephalopathy should improve post- 
transplant as liver function normalizes.  Careful monitoring of the patient’s mental status is 
required with any subtle change noted to the transplant team.  High immunosuppression levels or 
electrolyte imbalances can cause seizure activity.   
Immunosuppression  
Common immunosuppressant agents are listed in Table 3.  Transplant centers have specific 
protocols for immunosuppression dosing, monitoring and therapeutic drug levels related to post 
transplant time periods. 
TABLE 3 
Immunosuppressive Agents 
Drug       Class 
Cyclosporine calcineurin inhibitor(CNI) 
 
Tacrolimus  calcineurin inhibitor (CNI) 
Sirolimus or Everolimus Inhibitor of mechanistic target of Rapamycin 
(MTOR) 
Mycophenolate mofitel Inhibitor of mechanistic target of Rapamycin 
(MTOR) 







Long Term Follow Up 
 Long term management of the liver transplant patient becomes a joint venture between the 
primary care provider in the local community and the transplant center.  Co-management can 
ensure the best patient outcomes.  Transplant centers have specific protocols for the timing of 
transplant labs, including immunosuppression levels, protocol liver biopsies, and specific 
diagnostic testing based on the patient’s diagnosis at time of transplant.   Primary care providers 
are involved with providing preventative care and managing complications of long term 
immunosuppression.  Transplant patients must be monitored and treated for renal insufficiency, 




1.United Network  for Organ Sharing [US]. https://www.unos.org/data/.  Accessed June 11, 
2017.  
2.Gaglio, PJ, Brown, RS Who should treat liver transplant patients?  The ransplant hepatologist 
or the gastroenterologist? Journal of Hepatology, 2006;44:655-657. 
3.Nyckowski,P, Skwarek,S, Zieniewicz,K et al. Orthotopic liver transplant for fulminant hepatic 
failure. Transplantation Proceedings, 2006;38:219-220. doi:10.1016/j.transproceed.2005.12.010. 
4.Arvelakis, A.,Katz,J., Manzarbeitia, C. Emedicine. Liver transplantation workup. 
http://emedicine.medscape.com/article/431783-workup 
5.Peyton,A., Martin,P. American Association for the Study of Liver Disease. Selection for liver 
transplantation. onlinelibrary.wiley.com/doi/10.1002/cld.218/pdf 
6.Farkas,S,  Hackl,C , Schlitt, H Overview of the indications and contraindications for liver  
transplant . Am J Transplant. 2011,11(9): 1773-1784. . doi:  10.1111/j.1600-6143.2011.03587.x 
7.Rudow,D, Goldstein,M. Critical care management of the liver transplant recipient. Critical 
Care Nursing Quarterly. 2008; 31(3): 232-243. 
http://ovidsp.tx.ovid.com.exp.waldenulibrary.org/p-3.25.0a/ovidweb.cgi. Accessed May 
25,2017.  
8.Martin, EF, O’Brien,C,  Update on MELD and organ allocation.          
onlinelibrary.wiley.com/doi/10.1002/cld.464/pdf  Accessed June,13, 2017. 
9.https://www.transplantpro.org/news/board-approves-national-liver-review-board-and-patient-
guidance/ 
10.Hansen,L, Yan,Y, Rosenkranz,S. The power of the liver transplantation waiting list:a case 
presentation. American Journal of Critical Care, 2014, 23(6): 510-515. 
11.Patton,H, Misel,M, Gish,R. Acute Liver Failure in Adults: An Evidence-Based   Management     
Protocol for Clinicians. Gastroenterol Hepatol . 2012; 8(3): 161–212. 
   https://www.ncbi.nlm.nih.gov › NCBI › Literature › PubMed Central (PMC) 
12.Wertheim, JA ,Petrowsky,H, Saab,S, Kupiec-Weglinski, J, Busuttil,R.  Major Challenges   
Limiting Liver Transplantation in the United States. Am J Transplant. 2011;11(9): 1773–
1784. doi:  10.1111/j.1600-6143.2011.03587.x 
13. Russ,P, Karani,J, Garg,K. Imaging of Liver Transplant Complications 
http://emedicine.medscape.com/article/375855-overview#a2 
14.  Kochhar,G,  Jose Mari Parungao, JM, Ibrahim A Hanouneh,IA, and Mansour A 
Parsi,MA.Biliary Complications Following World J Gastroenterol. 2013; 19(19): 2841-
2846.  Doi:10.3748/wjg.v19.i19.2841 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
